New ulcerative colitis treatment to be rolled out on NHS

More than 25,000 people with moderately to severely active ulcerative colitis in England are set to benefit from a new targeted treatment. NICE has recommended etrasimod (Velsipity) as a treatment option for people aged 16 and over who have had an inadequate response, lost response or were intolerant to either conventional therapy or biological treatment. The once-a-day tablet has been shown to improve symptoms by reducing inflammation in the colon by helping to control the level of immune cells in the blood. The new treatment option should be available on the NHS within the next three months. Ulcerative colitis affects